Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249

Article  PubMed  Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396(10251):635–648

Article  CAS  PubMed  Google Scholar 

Sato Y, Okamoto K, Kida Y, Mitsui Y, Kawano Y, Sogabe M, Miyamoto H, Takayama T (2023) Overview of chemotherapy for gastric cancer. J Clin Med 12(4):1336

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957

Article  PubMed  Google Scholar 

Karati D, Kumar D (2023) A comprehensive review on targeted cancer therapy: new face of treatment approach. Curr Pharm Des 29(41):3282–3294

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476–484

Article  PubMed  Google Scholar 

Shah AA, Kamal MA, Akhtar S (2021) Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Curr Drug Metab 22(1):50–59

CAS  PubMed  Google Scholar 

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H et al (2015) FDA approval summary: ramucirumab for gastric cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 21(15):3372–3376

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J et al (2015) The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 26(6):1244–1248

Article  PubMed  Google Scholar 

Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A et al (2023) Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41(7):1470–1491

Article  CAS  PubMed  Google Scholar 

Nakayama I, Takahari D (2023) The role of angiogenesis targeted therapies in metastatic advanced gastric cancer: a narrative review. J Clin Med 12(9):3226

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdelsalam EA, Abd El-Hafeez AA, Eldehna WM, El Hassab MA, Marzouk HMM, Elaasser MM, Abou Taleb NA, Amin KM, Abdel-Aziz HA, Ghosh P et al (2022) Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. J Enzyme Inhib Med Chem 37(1):2265–2282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura Y, Mikami J, Makari Y, Fujii C, Hiraki Y, Imano M, Fujita J, Yasuda T (2019) Proteinuria in patients with gastric cancer treated with ramucirumab. Gan To Kagaku Ryoho 46(2):245–249

CAS  PubMed  Google Scholar 

Kimura Y, Makari Y, Mikami J, Hiraki Y, Kato H, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M et al (2017) A case of recurrent gastric cancer with grade 3 proteinuria caused by ramucirumab plus paclitaxel therapy. Gan To Kagaku Ryoho 44(12):1080–1082

PubMed  Google Scholar 

Kobashi M, Kanzaki H, Okada H (2021) Perforation of gastric metastasis during chemotherapy with ramucirumab. Curr Probl Cancer 45(2):100666

Article  PubMed  Google Scholar 

Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim T-Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology 15(11):1224–1235

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (london, england) 383(9911):31–39

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J et al (2019) Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):420–435

Article  CAS  PubMed  Google Scholar 

Yoshikawa T, Muro K, Shitara K, Oh D-Y, Kang Y-K, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y et al (2019) Effect of first-line S-1 plus oxaliplatin with or without ramucirumab followed by paclitaxel plus ramucirumab on advanced gastric cancer in East Asia the phase 2 RAINSTORM randomized clinical trial. JAMA Netw Open 2(8):e198243

Article  PubMed  PubMed Central  Google Scholar 

Xu R-H, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B et al (2021) Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised multicentre, double-blind, phase 3 trial. Lancet Gastroenterology & Hepatology 6(12):1015–1024

Article  Google Scholar 

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD et al (2016) Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. Ann Oncol 27(12):2196–2203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung HC, Kok VC, Cheng R, Hsu Y, Orlando M, Fuchs C, Cho JY (2018) Subgroup analysis of East Asian patients in REGARD: a phase III trial of ramucirumab and best supportive care for advanced gastric cancer. Asia Pac J Clin Oncol 14(3):204–209

Article  PubMed  Google Scholar 

Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y et al (2016) Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19(3):927–938

Article  CAS  PubMed  Google Scholar 

Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K et al (2016) Subgroup analysis of East Asians in RAINBOW: a phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. J Gastroenterol Hepatol 31(3):581–589

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33(30):3416–3422

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708

Article  CAS  PubMed  Google Scholar 

Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M et al (2020) Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer  (Oxford, England: 1990) 137:272–284

CAS  Google Scholar 

Turkes F, Chau I (2019) Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future oncology (London, England) 15(9):979–988

Article  CAS  PubMed  Google Scholar